Medicines acting on IL5
Interleukin 5. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
Medicines acting on IL5
most-trialled first| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Mepolizumab CHEMBL2108429 |
Interleukin-5 inhibitor Inhibitor Antibody |
ChEMBL only | 16 |
| Depemokimab CHEMBL4650469 |
Interleukin-5 inhibitor Inhibitor Antibody |
ChEMBL only | 10 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
Diseases these medicines are tested for
by number of IL5 medicines| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Chronic obstructive pulmonary disease | 2 | Phase 3 |
| Chronic rhinosinusitis with nasal polyps | 2 | Phase 3 |
| Eosinophilic granulomatosis with polyangiitis | 2 | Phase 3 |
| Granulomatosis with polyangiitis | 2 | Phase 3 |
| Hypereosinophilic syndrome | 1 | Phase 3 |
| Nasal cavity polyp | 1 | Phase 3 |
| Dysphagia | 1 | Phase 2 |
| Nasal polyposis | 1 | Phase 2 |
| Atopic eczema | 1 | Phase 2 |
| Bullous pemphigoid | 1 | Phase 2 |
| Coronary artery disorder | 1 | Phase 2 |
| Eosinophilic esophagitis | 1 | Phase 2 |
| Increased total eosinophil count | 1 | Phase 1 |
| Chronic idiopathic urticaria | 1 | Early phase 1 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
How this page is built
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
- Open Targets Platform, target ENSG00000113525 ↗ target record, CC0 1.0
- ChEMBL mechanism of action and drug indication data ↗ curated by EMBL-EBI, CC BY-SA 3.0
- IUPHAR/BPS Guide to PHARMACOLOGY 2026.3.1 ↗ expert-curated ligand-target interactions; database ODbL, contents CC BY-SA 4.0
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 31 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.